Last reviewed · How we verify

NCT03276325

Epidural Steroids With Intrathecal Nalbuphine for Lower Abdominal Oncologic Surgery

Completed NA Last updated 9 January 2018
What this trial tests

NA trial testing Placebo-nalbuphine in Lower Abdominal Oncologic Surgery in 70 participants. Completed in 7 January 2018.

Timeline
15 September 2017
Primary endpoint
1 January 2018
7 January 2018

Quick facts

Lead sponsorMansoura University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeother
Enrollment70
Start date15 September 2017
Primary completion1 January 2018
Estimated completion7 January 2018
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Mansoura University

Who can join

Adults 18 to 60, any sex, with Lower Abdominal Oncologic Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intraoperative pain, nausea, vomiting, hypotension, bradycardia are known side effects during lower abdominal surgery under spinal anesthesia, Time to 2 segment regression of sensory block and duration of effective analgesia prolonged with intrathecal (IT) 0.4 mg nalbuphine \& IT 0.8 mg nalbuphine, but the incidence of side-effects was significantly higher with IT 0.8 mg nalbuphine compared with (IT) 0.4 mg nalbuphine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Mansoura University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03276325.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing